Boothwyn Pharmacy

• Pharmacy Profile Name: Boothwyn Pharmacy, LLC
• Website: boothwyn.com
• Address: 221 Gale Lane, Kennett Square, PA 19348
• Phone: 1-800-476-7496
• Pharmacist-in-Charge: Wayne C. Sartorio
• Pharmacy Type: 503A state-licensed compounding pharmacy
• GLP-1 Status: Production voluntarily suspended June 2025

About the Pharmacy

Boothwyn Pharmacy is pharmacist-owned and pharmacist-operated, with 90% of orders shipped within 48 hours via two-day delivery. It built a significant presence in the compounded GLP-1 space through telehealth partnerships and a patient-facing website focused on weight loss injections. That reputation has since been substantially undermined by one of the most serious regulatory enforcement records of any pharmacy.

GLP-1 Compounding

Boothwyn compounded both semaglutide and tirzepatide as sterile injectables. Its stated quality approach was more transparent than most compounders — the pharmacy elected to perform potency, sterility, and endotoxin testing on every compounded sterile GLP-1 batch, going beyond what USP <797> standards require, and dispensed medication only after results were verified by its Quality Assurance team, with test results accessible to patients through a secure online portal.

In practice, however, FDA inspections found serious gaps between those stated standards and actual facility conditions — ultimately leading to a subpotency recall and a voluntary production suspension.

Current GLP-1 Status: As of June 30, 2025, Boothwyn agreed with the FDA to temporarily cease all sterile injectable GLP-1 production and to notify the FDA prior to resuming. Whether production has since resumed has not been publicly confirmed.

The enforcement timeline behind that suspension is detailed below:

• 2018 — FDA Warning Letter after a 2017 inspection found serious deficiencies in sterile drug production that put patients at risk
• 2021 & 2023 — Additional FDA Form 483s, with 2023 findings including no continuous cleanroom pressure monitoring, non-sterile wipes used in ISO 5 areas, and inadequate cross-contamination controls
• 2025 — Pennsylvania fined Boothwyn $1 million for compounding ~30,000 GLP-1 doses in uninspected, unlicensed spaces — concealed from inspectors across four separate state inspections
• July 2025 — Voluntary recall of compounded semaglutide 2.5 mg/mL (1,476 total vials across three sizes) due to subpotency
• January 2026 — FDA Warning Letter citing sterility failures, subpotent semaglutide and tirzepatide formulations, and sterile products distributed before final sterility results were confirmed
• California — Board of Pharmacy proceedings alleging eleven lots of compounded sterile preparations failed strength and purity requirements, and that an executive presented false and misleading documents to a state inspector

Type of Pharmacy

Boothwyn Pharmacy LLC is a 503A state-licensed compounding pharmacy. As a 503A facility, it is regulated primarily by state boards of pharmacy rather than directly by the FDA, though the FDA retains authority to inspect 503A facilities and issue warning letters for federal violations — which it has done multiple times with Boothwyn. It is not an FDA-registered 503B outsourcing facility and does not operate under the stricter cGMP manufacturing standards that 503B designation requires.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

States Licensed In

Boothwyn shipped nationally during its active GLP-1 operation, suggesting broad state licensing. However, its state licensing footprint is not comprehensively listed on its public website. The Pennsylvania fine and California Board of Pharmacy proceedings confirm that at least two state regulatory bodies have taken action against the pharmacy. Current active state licensing should be verified directly with Boothwyn or through the relevant state board before placing any prescription.

Telehealth Providers They Work With

Remedy Meds is a publicly confirmed telehealth partner of Boothwyn Pharmacy. Remedy Meds connects patients with licensed clinicians and lists Boothwyn as its compounding pharmacy partner for GLP-1 prescriptions, noting the pharmacy’s two-day shipping and pharmacist-operated model as quality signals.

Other telehealth platforms that may have used Boothwyn during the GLP-1 shortage era are not comprehensively named in public records. Given the June 2025 production suspension, any platform previously listing Boothwyn as a partner should be contacted directly to confirm whether Boothwyn currently fills GLP-1 prescriptions for their patient network.

Pricing from Reviews

Pricing for Boothwyn-compounded GLP-1 medications was set by partner telehealth platforms, not by Boothwyn directly. No consistent patient-facing price data for Boothwyn-sourced medication is publicly available. Patients accessed Boothwyn’s compounded products through their telehealth provider’s pricing structure — typically in the $150–$350/month range that characterized the broader compounded GLP-1 market during the shortage era.

Overall Reviews

Before the enforcement actions surfaced publicly, patient reviews of Boothwyn noted fast and reliable shipping and the sense of personalized care that comes with a pharmacist-owned operation. Those positives have been overtaken by the regulatory record.

The combination of a $1 million state fine, a voluntary subpotency recall covering nearly 1,500 vials, a voluntarily suspended GLP-1 production line, a January 2026 FDA Warning Letter citing insanitary conditions and sterility failures, and California Board of Pharmacy proceedings alleging falsified compounding records collectively represent the most serious compliance failure of any pharmacy reviewed in this series. Patients who received Boothwyn-compounded GLP-1 medications between September 2024 and July 2025 should discuss the subpotency recall with their prescribing provider to determine whether their specific lot was affected.